Current Peptide Compliance

The “Research Use Only” (RUO) label has long served as a gray-area shield for peptide suppliers seeking to avoid full FDA regulatory oversight. That era is ending. The FDA has dramatically increased enforcement against companies marketing peptides as RUO while effectively selling them for human use, and the consequences are severe.

What RUO Actually Means

Legitimate research-use-only products are intended exclusively for laboratory research and are not for administration to humans. The RUO designation does not exempt a product from all FDA regulation — it means the product is not being marketed as a drug. The moment a company’s marketing, packaging, customer base, or sales patterns suggest the product is intended for human use, the RUO designation becomes legally indefensible.

Recent Enforcement Actions

The FDA has targeted RUO peptide suppliers through warning letters, import alerts, and criminal referrals. Common triggers include websites that discuss clinical benefits, customer lists dominated by wellness clinics rather than research institutions, dosing instructions that mirror clinical use, and packaging in vial sizes consistent with patient administration rather than laboratory quantities.

Compliance Path Forward

Companies genuinely operating in the research peptide space need clear documentation of their research-only intent: customer qualification procedures, end-use certifications, marketing material reviews, and distribution controls that demonstrate products are reaching legitimate research customers. Companies that are actually selling for human use should explore proper FDA-regulated pathways rather than relying on an RUO label that invites enforcement.

Concerned about RUO compliance risks? Current Peptide Compliance helps companies evaluate their regulatory exposure and build defensible compliance programs. Schedule a consultation.